Gurpreet Kaur1, Geeta Gathwala2. 1. Department of Pediatrics, Pandit B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana 124001, India gurpreet.virgo@gmail.com. 2. Department of Pediatrics, Pandit B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana 124001, India.
Abstract
OBJECTIVES: To evaluate the efficacy of bovine lactoferrin (BLF) in preventing first episode of late-onset sepsis (LOS) in low birth weight (LBW) neonates. METHODS: In this study conducted from May 2012 to July 2013 in the neonatal intensive care unit (NICU) of a tertiary care hospital, inborn asymptomatic neonates, <2000 g, admitted to NICU in first 12 h of birth with no maternal risk factors for sepsis were randomized to receive BLF or placebo from 1st to 28th day of life. The incidence of culture-proven sepsis and sepsis-attributable mortality after 72 h of life was recorded. Increasing doses of BLF were used with higher birth weights. RESULTS:Incidence of first episode of culture-proven LOS was significantly lower in the BLF group vs. placebo [2/63 (3.2%) vs. 9/67(13.4%); risk ratio, 0.211; 95% CI, 0.044-1.019; p = 0.036]. Statistically significant reduction in the sepsis-attributable mortality was also seen after use of prophylactic BLF [0/63 (0%) vs. 5/67 (7.5%); p = 0.027]. CONCLUSION:BLF supplementation in LBW neonates reduced the incidence of first episode of LOS.
RCT Entities:
OBJECTIVES: To evaluate the efficacy of bovinelactoferrin (BLF) in preventing first episode of late-onset sepsis (LOS) in low birth weight (LBW) neonates. METHODS: In this study conducted from May 2012 to July 2013 in the neonatal intensive care unit (NICU) of a tertiary care hospital, inborn asymptomatic neonates, <2000 g, admitted to NICU in first 12 h of birth with no maternal risk factors for sepsis were randomized to receive BLF or placebo from 1st to 28th day of life. The incidence of culture-proven sepsis and sepsis-attributable mortality after 72 h of life was recorded. Increasing doses of BLF were used with higher birth weights. RESULTS: Incidence of first episode of culture-proven LOS was significantly lower in the BLF group vs. placebo [2/63 (3.2%) vs. 9/67(13.4%); risk ratio, 0.211; 95% CI, 0.044-1.019; p = 0.036]. Statistically significant reduction in the sepsis-attributable mortality was also seen after use of prophylactic BLF [0/63 (0%) vs. 5/67 (7.5%); p = 0.027]. CONCLUSION:BLF supplementation in LBW neonates reduced the incidence of first episode of LOS.
Authors: Theresa J Ochoa; Jaime Zegarra; Sicilia Bellomo; Cesar P Carcamo; Luis Cam; Anne Castañeda; Aasith Villavicencio; Jorge Gonzales; Maria S Rueda; Christie G Turin; Alonso Zea-Vera; Daniel Guillen; Miguel Campos; Linda Ewing-Cobbs Journal: J Pediatr Date: 2020-02-06 Impact factor: 4.406
Authors: Rían Hayes; Jack Hartnett; Gergana Semova; Cian Murray; Katherine Murphy; Leah Carroll; Helena Plapp; Louise Hession; Jonathan O'Toole; Danielle McCollum; Edna Roche; Elinor Jenkins; David Mockler; Tim Hurley; Matthew McGovern; John Allen; Judith Meehan; Frans B Plötz; Tobias Strunk; Willem P de Boode; Richard Polin; James L Wynn; Marina Degtyareva; Helmut Küster; Jan Janota; Eric Giannoni; Luregn J Schlapbach; Fleur M Keij; Irwin K M Reiss; Joseph Bliss; Joyce M Koenig; Mark A Turner; Christopher Gale; Eleanor J Molloy Journal: Pediatr Res Date: 2021-11-06 Impact factor: 3.756
Authors: Jacky Lu; Jamisha D Francis; Miriam A Guevara; Rebecca E Moore; Schuyler A Chambers; Ryan S Doster; Alison J Eastman; Lisa M Rogers; Kristen N Noble; Shannon D Manning; Steven M Damo; David M Aronoff; Steven D Townsend; Jennifer A Gaddy Journal: Chembiochem Date: 2021-03-23 Impact factor: 3.461